Puig, L., Bakulev, A. L., Kokhan, M. M., Samtsov, A. V., Khairutdinov, V. R., Morozova, M. A., . . . Zinkina-Orikhan, A. V. (2021). Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatology and therapy, 11(4), 1319-1332. https://doi.org/10.1007/s13555-021-00554-4
Citace podle Chicago (17th ed.)Puig, Luís, et al. "Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial." Dermatology and Therapy 11, no. 4 (2021): 1319-1332. https://doi.org/10.1007/s13555-021-00554-4.
Citace podle MLA (9th ed.)Puig, Luís, et al. "Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial." Dermatology and Therapy, vol. 11, no. 4, 2021, pp. 1319-1332, https://doi.org/10.1007/s13555-021-00554-4.